Supernus Pharmaceuticals

What Supernus Pharmaceuticals does

Supernus Pharmaceuticals, Inc. is a publicly traded specialty biopharmaceutical company (NASDAQ: SUPN) headquartered in Rockville, Maryland, with more than 30 years of experience developing and commercializing treatments for central nervous system (CNS) diseases. The company develops, manufactures, and markets nine branded prescription products spanning five therapeutic areas: ADHD (Qelbree), Parkinson's disease (Onapgo, Gocovri, Apokyn, Xadago), postpartum depression (Zurzuvae, via Biogen collaboration), epilepsy and migraine (Trokendi XR, Oxtellar XR), and cervical dystonia/sialorrhea (Myobloc). It sells primarily to U.S. specialty prescribers—neurologists, psychiatrists, and movement-disorder specialists—through dedicated specialty sales forces, while out-licensing international commercialization to other pharmaceutical partners.

The product franchise is anchored by a proprietary drug delivery and formulation technology platform that has produced ten marketed products, including own-brand launches (Qelbree, Trokendi XR, Oxtellar XR) and products developed for Shire/Takeda (Adderall XR, Intuniv, Mydayis) and United Therapeutics (Orenitram). Supernus has materially supplemented internal R&D through two acquisitions: Adamas Pharmaceuticals in November 2021 (~$450M) added GOCOVRI and Osmolex ER, and Sage Therapeutics in July 2025 (~$561–795M) added ZURZUVAE. Two Phase 2 pipeline candidates—SPN-820/821 for treatment-resistant depression and SPN-817 for severe epilepsy—are advancing toward 2027 top-line readouts.

Supernus generates revenue through (1) direct U.S. product sales via its specialty sales force, with four designated growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—representing approximately 76% of total revenue; (2) collaboration and milestone revenue from the Biogen partnership for ZURZUVAE; and (3) out-licensing royalties for international territories. FY2025 revenue was $719M with 40% growth in the four-product growth franchise, and management is guiding FY2026 revenue of $840–870M (17–21% growth). Supernus operates debt-free with $384M in cash and a market capitalization of approximately $2.53–2.90B.

Name

Supernus Pharmaceuticals

Legal name

Supernus Pharmaceuticals, Inc.

Website

http://www.supernus.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Supernus Pharmaceuticals (NASDAQ: SUPN) is a Rockville, MD-based specialty biopharmaceutical company that develops and commercializes branded prescription drugs for central nervous system diseases—including ADHD, Parkinson's, epilepsy, migraine, and postpartum depression—sold primarily through U.S. specialty sales forces to neurologists and psychiatrists.

Ownership category

akta.pro rank

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Product sales (commercial CNS portfolio): Direct sales of marketed CNS products (Qelbree, Trokendi XR, Oxtellar XR, GOCOVRI, ONAPGO, Apokyn, Myobloc, Xadago) through US specialty sales forces; Q1 2026 Qelbree sales of $78M, GOCOVRI $35.2M.
2. Collaboration revenues (ZURZUVAE with Biogen): Collaboration revenue from Biogen partnership for ZURZUVAE (zuranolone), including $27.6M in Q1 2026 and $15M regulatory milestone in Q4 2025.
3. International licensing (out-licensing): Licensing of products to other pharmaceutical companies for commercialization outside the United States through strategic collaborations.
4. Specialty pharmacy / HCP-channel distribution: Distribution of branded CNS therapies through healthcare providers, specialty pharmacies, and HUB partners with patient access programs.

Pricing tiers

Go-to-market motion3 records

Distribution channels1 record

Marketing channels7 records

Core offering

Supernus Pharmaceuticals develops and commercializes a portfolio of FDA-approved branded central nervous system (CNS) prescription drugs across ADHD, Parkinson's disease, epilepsy, migraine, postpartum depression, and cervical dystonia, supported by a pipeline of investigational candidates. Its current commercial portfolio includes nine marketed products (Qelbree, Onapgo, Gocovri, Zurzuvae, Apokyn, Myobloc, Oxtellar XR, Trokendi XR, Xadago) built largely on proprietary drug delivery technology, with products sold in the United States through dedicated specialty sales forces and abroad via licensing partnerships.

Product overview

Supernus Pharmaceuticals operates as a specialty biopharmaceutical company with a diverse, franchise-style CNS pharmaceutical portfolio rather than a unified software platform. Its nine marketed products are organized around five therapeutic areas: ADHD (Qelbree), Parkinson's disease (Onapgo, Gocovri, Apokyn, Xadago), postpartum depression (Zurzuvae, developed in collaboration with Biogen), epilepsy and migraine (Trokendi XR, Oxtellar XR), and cervical dystonia / sialorrhea (Myobloc). Four of these — Qelbree, GocOVRI, ZURZUVAE, and ONAPGO — are designated as Supernus's growth products and accounted for ~76% of Q4 2025 revenues, while Oxtellar XR, Trokendi XR, Myobloc, Apokyn, and Xadago are legacy products (Trokendi XR and Oxtellar XR face loss of exclusivity). The portfolio was assembled through internal R&D using Supernus's proprietary drug delivery technologies — which were also used to develop Adderall XR, Intuniv, and Mydayis for Shire (now Takeda), and Orenitram for United Therapeutics Corporation — supplemented by the 2021 Adamas Pharmaceuticals acquisition (adding GOCOVRI) and the 2025 Sage Therapeutics acquisition (adding ZURZUVAE). The portfolio is extended by an internal pipeline that includes SPN-820/821 for treatment-resistant depression and SPN-817 for severe epilepsy, with Phase 2b data readouts targeted for 2027. Commercial operations in the United States are executed through Supernus's own specialty sales forces, while international commercialization is pursued via strategic collaborations.

Differentiator

Problem solved

Functional benefit

Brands

• Qelbree: Treatment for Attention Deficit/Hyperactivity Disorder (ADHD)
• Onapgo
• Gocovri
• Zurzuvae
• Apokyn
• Myobloc
• Oxtellar XR
• Trokendi XR
• Xadago

Products and services

• Qelbree (viloxazine extended-release) Supernus's proprietary non-stimulant extended-release treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in pediatric and adult patients; one of the company's four key growth products.
• Onapgo (apomorphine subcutaneous infusion) Continuous subcutaneous apomorphine infusion therapy for Parkinson's disease; recently launched growth product in Supernus's Parkinson's franchise.
• Gocovri (extended-release amantadine) Extended-release amantadine product for the treatment of dyskinesia in Parkinson's disease; obtained via the 2021 Adamas Pharmaceuticals acquisition.
• Zurzuvae (zuranolone) First FDA-approved oral 14-day treatment for postpartum depression; obtained via the 2025 Sage Therapeutics acquisition and commercialized in collaboration with Biogen.
• Apokyn (apomorphine injection) Apomorphine injection for the acute, intermittent treatment of hypomobility, 'off' episodes associated with advanced Parkinson's disease; part of Supernus's Parkinson's portfolio.
• Myobloc (rimabotulinumtoxinB injection) Injectable rimabotulinumtoxinB for the treatment of cervical dystonia and sialorrhea; part of Supernus's neurology portfolio and accompanied by a boxed warning.
• Oxtellar XR (extended-release oxcarbazepine) Extended-release oxcarbazepine for the treatment of partial-onset seizures in epilepsy; Supernus's first internally developed CNS product utilizing its proprietary drug delivery technology.
• Trokendi XR (extended-release topiramate) Extended-release topiramate for epilepsy and migraine prevention; built on Supernus's proprietary drug delivery technology; a legacy product now facing loss of exclusivity.
• Xadago (safinamide) Safinamide adjunct therapy for Parkinson's disease patients experiencing 'off' episodes; rounds out Supernus's Parkinson's franchise alongside Onapgo, Gocovri, and Apokyn.

Quantifiable outcome

• 40% revenue growth across four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) representing 76% of 2025 total revenues
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered major and minor.

• MERGEmajorGTM or Marketing Partner · 17 June 2026MERGE was selected as Supernus's expanded Agency of Record (AOR), extending a seven-year partnership that now unifies Supernus' digital marketing and technology platforms under a single agreement. MERGE assumes leadership of Supernus' full digital ecosystem including website development, CRM operations, and omnichannel marketing strategy. Coverage spans QELBREE (ADHD) and the Parkinson's disease portfolio (APOKYN, GOCOVRI, ONAPGO). MERGE's AI-first approach delivers hyper-personalized, compliant digital interactions across multiple sales forces.
• NavitorminorStrategic or Co-development Partner · 1 April 2026Supernus Pharmaceuticals Inc entered into an asset purchase agreement with Navitor on April 1, 2026. Supernus CEO Jack Khattar also serves on the board of directors of Navitor Pharmaceuticals, LLC.
• Sage TherapeuticsmajorStrategic or Co-development Partner · 31 July 2025Supernus completed the acquisition of Sage Therapeutics in July 2025, adding the FDA-approved product ZURZUVAE (zuranolone) for postpartum depression to its CNS portfolio. The deal was valued at approximately $561-$795 million (upfront cash + contingent value rights based on sales milestones). Expected to be accretive in 2026 with cost synergies expected to reach $200 million annually.
• BiogenmajorStrategic or Co-development Partner · 31 July 2025Strategic collaboration with Biogen for the commercialization of ZURZUVAE (zuranolone), the first FDA-approved oral treatment for postpartum depression. Supernus records collaboration revenue from this partnership (e.g., $27.6M in Q1 2026, $15M regulatory milestone in Q4 2025). Biogen received Health Canada authorization for ZURZUVAE in December 2025.
• Adamas PharmaceuticalsmajorStrategic or Co-development Partner · 24 November 2021Supernus completed the acquisition of Adamas Pharmaceuticals on November 24, 2021, including its portfolio of Parkinson's disease treatments GOCOVRI and Osmolex ER. The deal involved a cash offer plus contingent value rights based on milestones for GOCOVRI sales. Approximately 77.3% of Adamas shares were tendered. The deal significantly diversified Supernus's revenue base and was projected to be accretive in 2022.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Pfizer: Diversified global pharma with CNS-adjacent assets and historical CNS franchises; relevant as a potential acquirer and competitive benchmark for the broader CNS competitive environment facing Supernus.
• UCB: Global biopharma with a significant CNS franchise (epilepsy with Vimpat/Briviact, Parkinson's with Rytary) and immunology; broader portfolio than Supernus but a meaningful comparator in CNS specialty commercialization.
• H. Lundbeck A/S: Established global CNS specialty pharma with franchises in depression, migraine, and Parkinson's disease; broader portfolio and geographic reach than Supernus but directly comparable CNS therapeutic areas.
• Teva Pharmaceutical Industries: Large generic and specialty pharma with a CNS franchise (Austedo for Huntington's/chorea, Ajovy for migraine); not a pure CNS play but a broad incumbent competing in Supernus's therapeutic neighborhoods.

Direct peers

• Axsome Therapeutics: CNS-focused biopharma commercializing Auvelity (depression) and other CNS therapies; highly comparable in target indications (depression), public-company CNS specialty profile, and growth-stage commercial ramp.
• Neurocrine Biosciences: Neurology/CNS specialty biopharma with Ingrezza (movement disorders) and a broad CNS pipeline; comparable in CNS focus and franchise-style product portfolio, though larger and more diversified than Supernus.
• Corcept Therapeutics: Specialty CNS biopharma focused on Korlym (Cushing's) and oncology-adjacent CNS indications with a small commercial footprint and proprietary drug platform; similar specialty-CNS business model and target HCP channels.
• Acadia Pharmaceuticals: Specialty CNS biopharma with Nuplazid (Parkinson's disease psychosis) and a pipeline in CNS/neuropsychiatry; directly comparable to Supernus in CNS focus, product-portfolio approach, and US specialty sales force model.
• Jazz Pharmaceuticals: Specialty CNS biopharma with overlapping therapeutic areas including epilepsy (Xywav, Epidiolex) and psychiatry, comparable in size, public-company profile, and specialty sales force GTM motion to Supernus.

Others

• Sage Therapeutics: CNS biopharma and developer of ZURZUVAE (postpartum depression) acquired by Supernus in 2025; no longer an independent peer but historically the most directly comparable competitor in the PPD space and now integrated into Supernus's portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/supernus-pharmaceuticals-inc-

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries4 records

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Supernus Pharmaceuticals